loading...| Preferred Name |
ibandronate sodium |
|
| Synonyms |
Bondronate |
|
| Definitions |
The sodium salt of ibadronic acid, a synthetic nitrogen-containing bisphosphonate. Ibandronic acid inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1670" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1670" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000365963 |
|
| altLabel |
Bondronate Boniva ibandronate |
|
| CAS Registry |
138926-19-9 |
|
| cui |
C0772244 C1541222 C0918019 C0379199 |
|
| DATE FIRST PUBLISHED |
2004-04-23 |
|
| Date last modified |
2017-12-13 |
|
| definition |
The sodium salt of ibadronic acid, a synthetic nitrogen-containing bisphosphonate. Ibandronic acid inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1670" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1670" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C1670 |
|
| notation |
CDR0000365963 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
ibandronate sodium |
|
| tui |
T109 T121 |